Synthesis of platinum-modified MOF 2-Pt-FA as two-way enhanced photodynamic therapy drug, and application of platinum-modified MOF 2-Pt-FA in tumor treatment

A mof2-pt-fa, mof2-pt technology, applied in the application field of bidirectionally enhanced photodynamic therapy drugs in tumor treatment, can solve the problem of easy aggregation and light-induced quenching, poor targeting and aggregation ability, and unsatisfactory treatment effect. and other problems, to achieve the effect of enhancing the efficiency of PDT, mild synthesis conditions, and improving the effect of PDT

Inactive Publication Date: 2020-07-31
SOUTHEAST UNIV
View PDF6 Cites 16 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, so far, there are still some thorny problems: (1) most PSs have poor tumor targeting and aggregation ability, low payload, easy aggregation and light-induced quenching, etc.; (2) glutathione in cancer cells (GSH) levels are much higher (100-1000 times) than normal cells, and overexpressed glutathione can act as an antioxidant to scavenge ROS generated under light

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Synthesis of platinum-modified MOF 2-Pt-FA as two-way enhanced photodynamic therapy drug, and application of platinum-modified MOF 2-Pt-FA in tumor treatment
  • Synthesis of platinum-modified MOF 2-Pt-FA as two-way enhanced photodynamic therapy drug, and application of platinum-modified MOF 2-Pt-FA in tumor treatment
  • Synthesis of platinum-modified MOF 2-Pt-FA as two-way enhanced photodynamic therapy drug, and application of platinum-modified MOF 2-Pt-FA in tumor treatment

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0036] Example 1: Synthesis of MOF 2

[0037] AlCl 3 ·6H 2 A mixture of O (0.0125 mmol), cetyltrimethylammonium bromide (CTAB) (1 mmol) and TCPP (0.063 mmol) was dissolved in 5 mL of water and then added to 20 mL of polytetrafluoroethylene at 180 °C Ethylene-lined autoclave for 16 hours. Purple nanoparticles were obtained by centrifugation and washed three times with DMF, H2O and acetone. This product is referred to as MOF1. Thereafter, MOF 1 (170 °C under vacuum, overnight) (10 mg) and Cu(Ac) 2 ·H 2 A solution of O (0.08 mmol) in 2 mL of DMF was added to a 20 mL Teflon-lined autoclave at 100 °C for 24 h. The product was collected by centrifugation and washed sequentially with DMF, H 2 O and acetone washes 3 times. Store the obtained MOF 2 particles dry.

[0038] figure 2 (A) shows the TEM image of the synthesized nanoparticle MOF 2 with a size of 100–200 nm; figure 2 (C) shows the XRD image of the synthesized nanoparticle MOF 2 together with the simulated image....

Embodiment 2

[0039] Example 2: Synthesis of MOF 2-Pt

[0040] The specific steps for the synthesis of MOF 2-Pt were to combine MOF 2 nanoparticles (0.05 g) and H 2 PtCl 6 (20 mM, 1 mL) in 20 mL of water was stirred at room temperature for 1 h. Next, add 2 mL of NaBH to the solution 4 (4 mg mL -1 ), followed by vigorous stirring for 3 hours. Finally, the product was centrifuged and washed 3 times with water. The product is called MOF 2-Pt.

[0041] figure 2 (B) shows the TEM image and high-resolution lattice image of the synthesized nanoparticle MOF 2-Pt, with platinum nanoparticles ranging in size from 2 to 5 nm; figure 2(C) shows the XRD image of the synthesized nanoparticle MOF 2-Pt.

Embodiment 3

[0042] Example 3: Synthesis of MOF 2-Pt-FA

[0043] 1 mL of MOF 2-Pt nanoparticles (1 mg mL -1 ) solution with 50 μL FA-PEG-COOH (5 mg mL -1 ) was stirred at room temperature for 30 minutes. The obtained MOF 2-Pt-FA was subjected to centrifugation and then dispersed in water for further use.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a preparation method and application of platinum-modified metal organic material MOF 2-Pt-FA as a two-way enhanced photodynamic therapy drug. The preparation method is as follows: first, a two-dimensional MOF nano-sheet with Cu(II) as an active center is prepared, then a platinum nanoparticle is deposited on the surface of MOF 2, and then poly(ethylene glycol)-folic acid ismodified on the surface of MOF 2-Pt to enhance targeting and compatibility to obtain a nano-drug; after the targeted cell uptake of the nano-drug, Cu(II) in the MOF 2 can reduce a concentration of GSH, and thereby the level of light-triggered reactive oxygen species generated by MOF is enhanced; in addition, the platinum nanoparticle in the prepared drug has the catalase-like activity, and can decompose H2O2 in cells into O2 to alleviate the hypoxic environment of tumors; and experiments show that the combination of GSH exhaustion and hypoxia relief can significantly improve PDT efficiency. The metal organic nanomaterial disclosed in the invention can be used as a nano-drug for photodynamic therapy, and has the clinical potential for treating tumors.

Description

technical field [0001] The invention belongs to the technical field of biomedicine, and in particular relates to the application of a platinum-modified metal organic framework material MOF 2-Pt-FA as a two-way enhanced photodynamic therapy drug in tumor treatment. Background technique [0002] In recent years, photodynamic therapy (PDT) has emerged as a promising therapeutic approach, mainly relying on the generation of highly toxic reactive oxygen species (ROS) by photosensitizers (PS) upon light irradiation. PDT has attracted extensive attention due to its unique advantages, such as specific spatiotemporal selectivity, negligible invasiveness, and low systemic toxicity. However, so far, there are still some thorny problems: (1) most PSs have poor tumor targeting and aggregation ability, low payload, easy aggregation and light-induced quenching, etc.; (2) glutathione in cancer cells (GSH) levels are much higher (100-1000 times) than normal cells, and overexpressed glutathi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K41/00A61K31/80A61K33/243A61K47/54A61K47/60A61P35/00C08G83/00
CPCA61K41/0076A61K33/243A61K31/80A61K47/545A61K47/60A61P35/00C08G83/008A61K2300/00
Inventor 刘松琴吴亚锋陈子璇
Owner SOUTHEAST UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap